FDA accepts review for ANGLE’s Parsortix system for metastatic breast cancer by Lucy Parsons | Oct 20, 2020 | News | 0 System captures and harvests intact circulating tumour cells for analysis Read More
Parsortix test could avoid unnecessary prostate biopsies by Anna Smith | Sep 11, 2019 | News | 0 Currently, investigation of symptoms for prostate cancer is typically made via an invasive blood test. Read More
Angle’s ovarian cancer test could beat current standard by Selina McKee | Jul 5, 2017 | News | 0 UK liquid biopsy group Angle has released trial findings that indicate its Parsortix blood test has the potential to out-perform the current standard of care in detecting ovarian cancer. Read More